Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 9k
7 January 2021
Priority question for written answer  P-000063/2021
to the Commission
Rule 138
Andreas Glück (Renew)
 Subject: Negotiations and procurement contracts for SARS-Cov-19 virus vaccines developed and under development

In light of the current shortage of vaccine doses in the EU, there is an urgent need for transparency on the negotiations and procurement contracts relating to the vaccines developed and under development in order to avoid damage to the public image of the EU and its institutions.

1. Was the Commission free to choose vaccine manufacturers, or was there feedback from the Member States during the selection process, including demands concerning preference for certain manufacturers or equal treatment vis-à-vis other manufacturers?

2. Why did the Commission order only up to 300 million doses of vaccine in November, even though BioNTech offered significantly more?

3. Why was an additional order for the optional 100 million doses of the BioNTech vaccine not placed sooner when it became clear that the other vaccines would not be available until later?

Original language of question: DE
Last updated: 11 January 2021Legal notice - Privacy policy